Roche: Handful of good news in oncology and neurologyBUY, Fair Value CHF327 (+30%)
We had been expecting to get fresh data from clinical studies investigating atezolizumab in various tumour types but mainly in lung at the ECC congress, which was indeed the case, but today the reported headlines results from the ORATORIO trial are likely to make the front page of the healthcare news. For the first time, an MS drug is reporting positive outcomes in primary progressive multiple sclerosis (PPMS), a specific form of MS that affects 10-15% of people with MS and had no therapeutic option available so far. Ocrelizumab is likely to have here a clear differentiating factor.
For more information, please contact firstname.lastname@example.org